Can a smart immune cell with a kill switch beat tough lymphomas?
NCT ID NCT07729397
First seen Jul 27, 2026 · Last updated Jul 27, 2026
Summary
This Phase 1 trial tests a new type of cell therapy for people with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. The treatment uses a patient's own immune cells that are genetically engineered to recognize and attack CD30 on cancer cells, plus a built-in safety switch to control side effects. The main goal is to see if the treatment is safe, while also checking whether it can shrink tumors and how long the engineered cells last in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- engineered immune cells (C7R.CD30-CAR-EBVSTs) that target CD30 on lymphoma cells and include a safety switch
- What this could lead to
- If successful, this approach could offer a new treatment option for people with hard-to-treat CD30-positive lymphomas, potentially leading to durable remissions.
- What could go wrong
- This is an early Phase 1 trial with only 21 participants, so safety and effectiveness are not yet established. There are risks of serious side effects like cytokine release syndrome and organ toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- Could bone marrow from deceased donors cure blood cancers?
- New drug combo aims to boost lymphoma treatment
- Genetic blueprint guides new lymphoma cocktail
- Could an ALS drug clear the fog of chemo brain?
- Engineered immune cells take aim at Tough-to-Treat blood cancers